Patent intelligence · US
US 12257247
Targeted degradation of VAV1
Targeted degradation of VAV1
Patent details — US 12257247
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 25, 2025
- Expiration
- Mar 20, 2045
- Applicant
- Monte Rosa Therapeutics AG
- Claims
- 12
- CPC classes
- A61K, A61K31/4545, A61P, A61P1/04
Quick answer
US 12257247 (Targeted degradation of VAV1) is held by Monte Rosa Therapeutics AG. Status: granted. Granted Mar 25, 2025. Expires Mar 20, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Monte Rosa Therapeutics AG
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K31/4545, A61P, A61P1/04, A61P19/02, A61P35/00
More from Monte Rosa Therapeutics AG
Related pharmaceutical patents in our USPTO index.
-
US 12391663
Isoindolinone compounds
granted -
US 12378199
Rigidified pentadentate chelating agents useful for the [Al18F]2+ labelling of biomolecules
granted -
US 12280029
Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
granted -
US 12263143
Ionic channel modulation as a method for treating tumors through inflammasome activation
granted -
US 12214218
Perfusion modulated tumor dose sculpting with single dose radiotherapy
granted -
US 12070628
Low energy immune priming for treating cancer and metastasis
granted -
US 12011619
Low intensity focused ultrasound for treating cancer and metastasis
granted
Frequently asked questions
What is US patent 12257247?
US 12257247 (Targeted degradation of VAV1) is held by Monte Rosa Therapeutics AG. Status: granted. Granted Mar 25, 2025. Expires Mar 20, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12257247?
Monte Rosa Therapeutics AG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 72 pharmaceutical patents for this assignee.
When does US 12257247 expire?
Our index shows an expiration date of Mar 20, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.